TY - JOUR AU - Jan-Henning Klusmann, AU - Dirk Reinhardt, AU - Martin Zimmermann, AU - Bernhard Kremens, AU - Josef Vormoor, AU - Michael Dworzak, AU - Ursula Creutzig, AU - Thomas Klingebiel, PY - 2011/12/30 Y2 - 2024/03/29 TI - The role of matched sibling donor allogeneic stem cell transplantation in pediatric high-risk acute myeloid leukemia: results from the AML-BFM 98 study JF - Haematologica JA - haematol VL - 97 IS - 1 SE - Articles DO - 10.3324/haematol.2011.051714 UR - https://haematologica.org/article/view/6184 SP - 21-29 AB - Background The role of allogeneic stem cell transplantation in post-remission management of children with high-risk acute myeloid leukemia remains controversial. In the multi-center AML-BFM 98 study we prospectively evaluated the impact of allogeneic stem cell transplantation in children with high-risk acute myeloid leukemia in first complete remission.Design and Methods HLA-typed patients with high-risk acute myeloid leukemia, who achieved first complete remission (n=247), were included in this analysis. All patients received double induction and consolidation. Based on the availability of a matched-sibling donor, patients were allocated by genetic chance to allogeneic stem cell transplantation (n=61) or chemotherapy-only (i.e. intensification and maintenance therapy; n=186). The main analysis was done on an intention-to-treat basis according to this allocation.Results Intention-to-treat analysis did not show a significantly different 5-year disease-free survival (49±6% versus 45±4%, Plog rank=0.44) or overall survival (68±6% versus 57±4%, Plog rank=0.17) between the matched-sibling donor and no-matched-sibling donor groups, whereas late adverse effects occurred more frequently after allogeneic stem cell transplantation (72.5% versus 31.8%, PFischer